1 / 1

Oral Mucositis Market

Oral Mucositis refers to erythematous and ulcerative lesions of the oral mucosa observed in patients with cancer being treated with chemotherapy, and/or with radiation therapy to fields involving the oral cavity.<br><br>In 2017, the total incident cases of Oral Mucositis in the seven major markets was 1,418,879. Similarly, the total treated cases of Oral Mucositis in the 7MM was 1,021,399.<br><br>As per the Delveinsight, the therapeutic market of Oral Mucositis in the 7MM was USD 1,052.7 million in 2017, which is expected to increase during the forecast period. <br><br>Increasing incidence of cancer patients, ongoing research & development and the robust pipeline activity are the key drivers for the Oral Mucositis Market. <br><br>The key players involved in developing therapies for Oral Mucositis includes Innovation Pharmaceuticals, Enzychem Lifesciences Corporation, BrainCool, NeoMedLight, Monopar Therapeutics, MuReva (Lumitex), EpicentRx/Prothex Pharma, Soligenix, Galera Therapeutics and others.<br><br>Source: Oral Mucositis Market<br><br>

DelveInsight
Télécharger la présentation

Oral Mucositis Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    More Related